In two phase 3 induction trials (U-EXCEL and U-EXCEED), we randomly assigned patients with moderate-to-severe Crohn’s disease to receive 45 mg of upadacitinib or placebo (2:1 ratio) once daily for 12 ...
Everyday Health on MSN
AAV treatment 101: Induction vs. maintenance
Learn the difference between induction and maintenance phases in ANCA-associated vasculitis (AAV) treatment, including what to expect from medications like rituximab (Rituxan).
IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.
Please provide your email address to receive an email when new articles are posted on . Significant improvements in clinical remission rates were observed at 12 weeks with risankizumab vs. placebo (20 ...
Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial Forty-three evaluable patients with common/pre-B (n ...
New ECCO dietary therapy guidelines for IBD clarify the role of enteral nutrition, Mediterranean diet, supplements, and RD ...
PATINA supports adding palbociclib to anti-HER2 plus endocrine therapy in HR+/HER2+ disease, and HER2CLIMB-05 validates tucatinib with HP after THP induction. Sequencing trials must address ADC ...
RIO DE JANEIRO — The addition of daratumumab to lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly improves rates of achieving minimal residual disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results